Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer.


When using chemotherapy in patients with a short life expectancy, outcomes such as symptom improvement or clinical benefit receive increasing attention. Outcomes of subjective benefit to the patient can be rated as a utility in order to perform health economic analyses and comparisons with other treatment conditions. A cost-utility analysis has been… (More)


  • Presentations referencing similar topics